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Abstract
Achondroplasia causes narrowing of the foramen magnum and the spinal canal leading to
increased mortality due to cervicomedullary compression in infants and significant morbidity due
to spinal stenosis later in adulthood. Vosoritide is a C-natriuretic peptide analogue that has been
shown to improve endochondral ossification in children with achondroplasia. The objective of this
trial is to evaluate the safety of vosoritide and whether vosoritide can improve the growth of the
foramen magnum and spinal canal in children that may require decompression surgery. An
Achondroplasia Foramen Magnum Score will be used to identify infants at risk of requiring decom-
pression surgery. This is a 2-year open label randomized controlled trial of vosoritide in infants
with achondroplasia ages 0 to 12months. Approximately 20 infants will be randomized 1:1 to
either open label once daily subcutaneous vosoritide combined with standard of care or standard
of care alone. The primary and secondary aims of the study are to evaluate the safety and efficacy
of vosoritide in children with cervicomedullary compression at risk of requiring decompression
surgery. The trial will be carried out in specialized skeletal dysplasia treatment centers with well
established multidisciplinary care pathways and standardized approaches to the neurosurgical
management of cervicomedually compression. After 2 years, infants randomized to standard of
care alone will be eligible to switch to vosoritide plus standard of care for an additional 3 years.
This pioneering trial hopes to address the important question as to whether treatment with
vosoritide at an early age in infants at risk of requiring cervicomedullary decompression surgery is
safe, and can improve growth at the foramen magnum and spinal canal alleviating stenosis. This in
turn may reduce compression of surrounding structures including the neuraxis and spinal cord,
which could alleviate future morbidity and mortality.
Trial registrations: ClinicalTrials.gov, NCT04554940; EudraCT number, 2020-001055-40
Keywords
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Background
Achondroplasia, the most common form of disproportionate short stature, is a rare
condition, with a prevalence of between 1/15,000 (www.orpha.net) and 1/25,000.1
The condition is caused by a gain-of-function pathogenic variant in the fibroblast
growth factor receptor 3 gene (FGFR3) that constitutively activates the mitogen-
activated protein kinase (MAPK) via the p38 and extracellular signal-regulated
kinase (ERK) pathways in chondrocytes, which inhibits endochondral ossification.2
Achondroplasia is de novo in the majority of cases (80%), and the most common
variant is the p.(Gly380Arg) substitution in the region encoding the transmembrane
domain of FGFR3.3 FGFR3 is one of many physiological regulators of linear bone
growth and normally functions as an inhibitor, acting negatively on both prolifera-
tion and terminal differentiation of chondrocytes, which are integral to endochon-
dral bone formation, the principal means for long-bone growth.4
In infancy and early childhood, the most important medical challenge driving
morbidity and mortality is narrowing of the foramen magnum, which has been
implicated in an excess of sudden deaths in children with achondroplasia under age
4 years.5,6 The foramen magnum is narrow in all individuals with achondroplasia
but individuals with signs and symptoms of cervicomedullary compression at the
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level of the foramen magnum tend to have critically stenosed foramen magnum
dimensions.7 The foramen magnum lies completely within the occipital bone and
its margins form and grow by endochondral ossification and are uniformly affected
in achondroplasia. Pathological foramen magnum stenosis, as seen in achondropla-
sia, is postulated to be secondary to hypertrophy of the occipital rim, overgrowth
of the opisthion and abnormal position and premature closure of skull base synch-
ondroses.8 Stenosis of the foramen magnum has the potential to compromise the
neural and vascular structures passing through this region and poses significant
medical risks to all children born with this condition. Compression of vital brain-
stem structures including central respiratory centers, cranial nerve nuclei and cra-
nial nerves can occur resulting in disordered breathing. Centrally mediated apnea, a
recognized complication of foramen magnum stenosis, is a likely contributory fac-
tor to the increased risk of sudden unexpected death in infancy, which is reported
to be as high as 7.5% in infants with achondroplasia.6,9
The base of the skull surrounding the foramen magnum has several synchon-
droses and these close at an earlier age in children with achondroplasia.10 Unlike
long bones, the foramen magnum attains 70%–80% of its final transverse and
sagittal diameter by 1 year of age and, although it continues to grow into adult-
hood, the rate is much slower. In average-stature children, the entire extent of
growth of the foramen magnum is around 1.5 cm in the transverse diameter and
2.4 cm in the sagittal diameter.7 In infants with achondroplasia, the growth of the
foramen magnum is significantly slower. The foramen magnum is small at birth
and grows at a significantly slower rate during the first 2 years, particularly in the
transverse diameter, as compared with average-statured children.7,11–13 Increasing
the growth rate of the foramen magnum in infancy could therefore be a crucial
advance in the clinical management of children with achondroplasia, but the chal-
lenges of identifying those infants at greatest risk and initiating treatment as soon
after birth as possible and at least before 2 years of age remain formidable.
Later in life, medical complications associated with the thoraco-lumbar spine
tend to be more prominent than those associated with the cervical spine.14 Short
pedicles, ligamentous thickening and kyphotic deformity compromise the caliber
of the spinal canal resulting in reduced space for the spinal cord and the cauda
equina.15 Exaggerated lumbar lordosis, anterior vertebral body wedging, and
thickening of the pedicles and laminae are additional factors that mean that the
spinal canal is one-third to one-half of the size of the canal in an individual of aver-
age stature. These features collectively contribute to a narrowed spinal canal as
well as adjacent spinal foramina resulting in a clinical picture of myelopathy and
radiculopathy.
Spinal growth is the product of more than 130 growth plates.16 The neurocentral
synchondroses in the spine are located at the junction of the pedicle and the verteb-
ral body and are important in the growth of the vertebral body and the posterior
arch. In average stature children, the neurocentral synchondroses fuse at approxi-
mately 9 years of age, and by 5 years of age the spinal canal has already grown to
approximately 95% of its final size.16 In children with achondroplasia the final size
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of the spinal canal is achieved even earlier. Therefore, similarly to the foramen mag-
num, increasing the growth rate of the spine in infancy could be another crucial
step forward in the clinical management of achondroplasia potentially benefitting
these individuals throughout their adult lives as well.
Current standard of care
Achondroplasia typically presents in the last trimester or at birth, so recognition
by neonatal and general pediatricians of early complications is important. Despite
efforts to publish expert consensus driven clinical guidelines, there is a lack of
alignment surrounding the need for and optimal timing and choice of screening
modality for cervicomedullary compression in infants with achondroplasia.8,15,17,18
The American Academy of Pediatrics recommends either CT or MRI to evaluate
changes at the foramen magnum in all infants with achondroplasia.15 However,
more recently best practice guidance based on expert consensus recommended that
MRI scans should be reserved for those infants with either an abnormal detailed
clinical neurological history and examination (performed every 2months for the
first year of life), or polysomnography abnormalities suggestive of foramen mag-
num stenosis.18 Abnormal neurological manifestations of foramen magnum steno-
sis include hypotonia, motor delay, feeding, and sleep disorders, and clinical
features of myelopathy such as hyper-reflexia and ankle clonus, which when pres-
ent strongly predict the need for decompression surgery in the infant popula-
tion.9,19 Neurological sequelae, however, are a late manifestation of high cervical
spinal cord compression and considerable experience of what is ‘‘normal’’ in
achondroplasia is required to determine what constitutes clinically significant find-
ings. Studies examining the predictive value of polysomnography or cardiorespira-
tory sleep study parameters in the identification of foramen magnum stenosis in
children with achondroplasia suggest low screening sensitivity.20,21 Neurosurgical
opinion regarding the need for surgery in the face of foramen magnum stenosis in
achondroplasia remains inconsistent and practice varies significantly between dif-
ferent centers, with rates of cervicomedullary decompression ranging from 4.6% to
43%.22,23 While the outcome of neurosurgical intervention is generally favorable,
severe complications, such as cerebrospinal fluid leakage, vascular injury, and wor-
sening neurological function, are well recognized.24
Having overcome the risks of surgery associated with foramen magnum stenosis
and cervicomedullary compression, as children with achondroplasia reach adoles-
cence and adulthood, they become at risk of symptomatic spinal canal stenosis
(particularly in the lumbar spine), which can lead to significant morbidity through-
out adult life.4,14 By 20 years of age, approximately 20% have abnormal neurologi-
cal signs. Back and leg pain occurs in up to 80% by the sixth decade of life.14
Worsening stenosis of the canal and foramina results in sensory dysfunction, radi-
cular pain, neurogenic claudication, bladder dysfunction, and, in severe cases, fecal
incontinence. About one-third require specialist laminectomy surgery for sympto-
matic spinal canal stenosis.4
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Recently, an Achondroplasia Foramen Magnum Score (AFMS) has been pro-
posed based on magnetic resonance imaging (MRI) of the cervicomedullary junc-
tion.25 The advantage of such a scoring system is that it relies on the progressive
effect of the decreased foramen magnum size on the neuraxis as opposed to mea-
surement of the dimensions of the foramen magnum. The advantage of such a scale
is that it is easily determined via objective MRI findings, is age independent and
does not require normalization. Further details of the scale are shown in Table 1.
This trial takes advantage of this easily qualifiable scoring system in order to evalu-
ate the progression of the score overtime and compare the intervention and control
groups.
C-natriuretic peptide and vosoritide
The binding of C-type natriuretic peptide (CNP) to its receptor, natriuretic peptide
receptor 2 (NPR2), inhibits FGFR3 downstream signaling at the level of Raf-1
and is a potent stimulator of endochondral ossification.26 CNP overexpression in a
transgenic mouse model is associated with skeletal overgrowth, including of the
axial and appendicular skeleton, craniofacial bones, and foramen magnum.27
Similarly, overexpression of CNP in the liver leading to increased serum CNP con-
centrations as well as continuous CNP infusions also rescue the craniofacial
abnormalities, skeletal, and foramen magnum abnormalities of an achondroplasia
mouse model.28,29 Furthermore, pathogenic variants that result in overexpression
of CNP in humans are also associated with enhanced skeletal growth, manifest by
abnormally tall stature, supporting the hypothesis that systemic therapy with CNP
should help ameliorate the skeletal phenotype of achondroplasia including at the
foramen magnum.30–32
Table 1. Achondroplasia foramen magnum score (AFMS).
AFM risk score MRI determined classification
AFMS 0 Normal cranio-cervical junction (CCJ)
AFMS 1 Narrowed cranio-cervical junction with cerebrospinal fluid (CSF)
surrounding the cord
AFMS 2 Loss of CSF signal surrounding the cord at the CCJ without cord remodeling
AFMS 2a Loss of CSF signal posterior to the cord
AFMS 2b Loss of CSF signal posteriorly and anteriorly
AFMS 2c Loss of CSF signal posteriorly, anteriorly and at the sides
AFMS 3 Remodeling of the cord at the CCJ
AFMS 3a CSF signal remains visible at the CCJ
AFMS 3b No CSF signal is visible at the CCJ
AFMS 4 High T2 signal in the cord at the CCJ
AFMS 4a CSF signal remains visible at the CCJ
AFMS 4b No CSF signal is visible at the CCJ
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Vosoritide is a recombinant CNP analogue that has been engineered to resist
degradation by neutral endopeptidase, allowing for a longer half-life and an impact
on endochondral ossification. Like CNP, vosoritide activates NPR2 signaling with
subsequent inhibition of FGFR3 downstream signaling, leading to the promotion
of chondrocyte proliferation and differentiation, and subsequent increased endo-
chondral bone formation.
Vosoritide administration restored impaired bone growth in a mouse model of
achondroplasia and improved bone growth in wild-type monkeys.33 These promis-
ing animal data led to an open-label, phase 2 study of vosoritide in children aged 5
to 14 years with achondroplasia.34 This study showed that vosoritide was generally
well tolerated at the doses tested and led to increases in annualized growth velocity
(AGV) that were maintained for up to 42months. This study was followed by a
pivotal, phase 3, randomized, placebo-controlled, double-blinded study of vosori-
tide in 121 children aged 5 to 18 years with achondroplasia, where 60 participants
were administered vosoritide and 61 a matching placebo for 52weeks.35 This study
confirmed the effectiveness of vosoritide through increasing AGV in the treated
group as compared to the placebo group, with similar side effect profiles observed
in treated and placebo groups.
Since most of the growth of the foramen magnum is achieved in the first 2 years
of life, vosoritide might be of benefit in young children with achondroplasia, by
increasing the growth of the foramen magnum, through its stimulatory effects on
endochondral ossification. Vosoritide therapy may consequently reduce the risk of
cervico-medullary compression, the morbidity and mortality associated with cervi-
comedullary compression, and the need for surgical decompression. Similarly,
since the growth of the spinal canal is completed by 9 years of age, increased
growth of the spinal canal during the first years of life, may also significantly
reduce spinal morbidity later in life. The primary aim of this study is to evaluate
the safety of daily subcutaneous vosoritide injections in infants and young children
with achondroplasia who are at increased risk of requiring surgical intervention
for cervicomedullary compression. The study will also explore the efficacy of
vosoritide in preventing the need for decompression surgery and contribute to the
understanding of the natural history of moderate foramen magnum stenosis
(AFMS grades 2 and 3).
Trial design and patient eligibility criteria
This is a stratified, randomized, controlled, open-label clinical study to investigate
the safety of vosoritide treatment in infants and young children with achondropla-
sia who are at risk of requiring cervicomedullary decompression surgery. Patients
aged 0 to 12months who have achondroplasia confirmed by genetic testing and
who meet the study eligibility criteria will be able to enroll directly into the study.
While the management of children with achondroplasia may vary among clinical
centers worldwide, this study will utilize an achondroplasia foramen magnum ste-
nosis risk score using MRI criteria to identify eligible children.25 Patient selection
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Table 2. Inclusion criteria.
Inclusion criteria
1. Parent(s) or guardian(s) willing and able to provide signed informed consent after the
nature of the study has been explained and prior to performance of any research related
procedure.
2. Have ACH, documented by genetic testing.
3. Are willing and able to perform all study procedures as physically possible.
4. Age 0 to 12months, at study entry (Day 1).
5. Parent(s) or caregiver(s) are willing to administer daily injections to the patient and
complete the required training.
6. Have evidence of cervicomedullary compression that ‘‘may’’ require surgical intervention
defined as:
s Baseline MRI assessment from central blinded evaluation showing at least one of the
following findings:
 Narrowing of the foramen magnum with loss of cerebrospinal fluid space
surrounding the cord.
 Narrowing of the foramen magnum with flattening of the cervical cord without T2
signal change.
s Supported by (but not required for eligibility) the following findings:
 Baseline physical examination
 Gross or fine motor developmental milestone delay compared to expected for
ACH (e.g. lifting head when lying on stomach).
 Abnormal reflex (e.g. brisk reflex/abnormal clonus for age).
 Weakness (e.g. opisthotonus).
 Baseline sleep study
Sleep apnea with a primary central component (e.g. not secondary to obstructive sleep apnea).
Exclusion criteria
1. Have hypochondroplasia or short-stature condition other than achondroplasia (e.g. trisomy
21, pseudoachondroplasia, etc.).
2. Have cervicomedullary compression that either does not require surgical intervention (e.g.
foramen magnum narrowing with preservation of the cerebrospinal fluid space) or does
require immediate surgical intervention (e.g. narrowing of the foramen magnum with
cervical cord signal change).
3. Have any of the following:
s Untreated congenital hypothyroidism or maternal history of hyperthyroidism.
s Insulin-requiring neonatal diabetes mellitus.
s Autoimmune inflammatory disease.
s Inflammatory bowel disease.
s Autonomic neuropathy.
(continued)
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Table 2. Continued
Inclusion criteria
4. Have a history of any of the following:
s Renal insufficiency.
s Chronic anemia.
s Baseline systolic blood pressure below age and gender specified normal range or
recurrent symptomatic hypotension (defined as episodes of low blood pressure generally
accompanied by symptoms [e.g. pallor, cyanosis, irritability, poor feeding]).
s Cardiac or vascular disease, including the following:
 Cardiac dysfunction (abnormal echocardiogram determined to be clinically
significant by investigator and medical monitor) at screening.
 Hypertrophic cardiomyopathy.
 Pulmonary hypertension.
 Clinically significant structural heart disease or valvular insufficiency (associated
with symptoms or requiring intervention).
 Clinically significant cerebrovascular disease.
 Aortic insufficiency or other clinically significant valvular dysfunction.
 Clinically significant atrial or ventricular arrhythmias.
5. Have a clinically significant finding or arrhythmia that indicates abnormal cardiac function or
conduction or QTc-Frederica ˜450ms on screening ECG.
6. Current treatment with antihypertensive medications, ACE inhibitors, angiotensin II
receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac glycosides,
systemic anticholinergic agents, any medication that may impair or enhance compensatory
tachycardia, drugs known to alter renal function that is expected to continue for the
duration of the study.
7. Require any other investigational product prior to completion of the study period.
8. Have received another investigational product or investigational medical device within
30 days prior to Screening.
9. Have used any other investigational product or investigational medical device for the
treatment of ACH or short stature at any time.
10. Require current chronic therapy with antihypertensive medication or any medication that,
in the Investigator’s judgment, may compromise the safety or ability of the patient to
participate in this clinical study.
11. Have been treated with growth hormone, insulin-like growth factor 1, or anabolic
steroids in the 6months prior to screening, or long-term treatment (.3months) at any
time.
12. Have had regular long-term treatment (.1month) with oral corticosteroids (low-dose
ongoing inhaled steroid for asthma, or intranasal steroids, are acceptable) prior to
screening.
13. Have ever had prior cervicomedullary decompression surgery.
14. Have had a fracture of the long bones or spine within 6months prior to screening.
15. Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or total
bilirubin .1.53 the upper limit of normal at Screening (except for patients with a known
history of Gilbert’s syndrome or transient indirect hyperbilirubinemia).
16. Have current malignancy, history of malignancy, or currently under work-up for suspected
malignancy.
17. Have known hypersensitivity to vosoritide or its excipients.




for entry into the study will be at specialized skeletal dysplasia units that routinely
perform MRI in infants with achondroplasia as per standard of care. Confirmation
of patient eligibility for the study will be performed through an independent
blinded central read of the MRI confirming that the patient has an AFMS of
AFMS2 defined as, ‘‘narrowing of the foramen magnum with loss of cerebrospinal
fluid space surrounding the cord’’ or AFMS3 defined as, ‘‘narrowing of the fora-
men magnum with flattening of the cervical cord without T2 signal change,’’25
thereby including patients who are not in immediate need for foramen magnum
decompression but nevertheless remain at risk of requiring it. A full list of all inclu-
sion and exclusion eligibility criteria are shown in Table 2.
Approximately 20 patients will be enrolled into the trial, stratified based on age
(0 to  6months, . 6months to  12months), and randomized 1:1 by a centra-
lized IXRS randomization to either open label, once daily, subcutaneous vosoritide
combined with standard of care (vosoritide + standard of care) or standard of
care alone. After 24months of randomized treatment, all patients may be eligible
to complete an additional 36months on-study receiving open-label vosoritide treat-
ment + standard of care. Patients will be enrolled at up to four clinical centers
worldwide. The overall study design is presented in Figure 1.
The primary objective is to assess the safety of daily subcutaneous vosoritide
+ standard of care versus standard of care alone when administered to infants
and young children with achondroplasia and signs and symptoms of cervicomedul-
lary compression. The secondary objective of the study is to evaluate the efficacy
of vosoritide in children who are at risk of requiring cervicomedullary decompres-
sion surgery.
Patients randomized to receive vosoritide will be administered the dose deter-
mined to be appropriate for their current age as identified in the ongoing Phase 2
randomized, double-blind, placebo-controlled clinical trial to evaluate the safety
Table 2. Continued
Inclusion criteria
19. Have a condition or circumstance that, in the view of the Investigator, places the patient
at high risk for poor treatment compliance or for not completing the study.
20. Have any concurrent disease or condition that, in the view of the Investigator, would
interfere with study participation or safety evaluations, for any reason.
While vitamin D deficiency (Vitamin D concentration\37.5 nmol/L or\15 ng/ml) is not an exclusion
criterion, it should be immediately treated with oral supplementation with 2000 IU daily and the value
repeated 4 weeks to confirm normalization of serum concentrations. Once achieved daily maintenance
dose is recommended.
If there is evidence of severe cervicomedullary compression, that ‘‘does’’ in the opinion of the
Investigator require surgical intervention then the child is not eligible to enroll. For example, the
presence of abnormal MRI T2 signal intensity at and immediately above and below the cervicomedullary
junction should be considered high risk for requiring surgery and the child would not be a candidate for
this trial.
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Figure 1. Study design.
This is a stratified, randomized, controlled, open-label clinical study to investigate the safety of vosoritide treatment in infants and young children with achondroplasia
at risk of requiring cervicomedullary decompression surgery. Approximately 20 patients, aged 0 to 12months who have documented achondroplasia confirmed by
genetic testing and who meet the study eligibility criteria will be eligible to enroll. Enrolled patients will be stratified based on age (0 to 6months, .6months to
12months) and will be randomized 1:1 to either open-label, once daily, subcutaneous vosoritide combined with standard of care (vosoritide + standard of care) or
standard of care alone. After 104weeks of randomized treatment, all patients will be eligible to complete an additional 156weeks on-study receiving open-label






and efficacy of vosoritide in infants and young children with ACH, aged 0 to\60
months (111-206; NCT03583697). The 111–206 study determined the appropriate
dose to achieve adequate exposure is age dependent with patients under 24months
of age requiring 30mg/kg/day and those older than 24months of age requiring
15mg/kg/day. Therefore reaching 24months of age is the criterion to de-escalate
the dose. The de-escalation will occur on the visit immediately preceding a patient
reaching 24months of age.
Safety outcome assessments
Safety in this study will be determined from evaluation of Adverse Events, Serious
Adverse Events, clinical laboratory assessments (chemistry, hematology), vital signs
measurements (heart rate, blood pressure, respiratory rate, and temperature), phys-
ical examinations, ECGs, echocardiograms, and concomitant medications.
Any abnormal laboratory test results determined to be clinically significant by
the Investigator will be repeated (at the Investigator’s discretion) along with any
necessary specialist consultation, until the cause of the abnormality is determined,
the value returns to baseline or to within normal limits, or the Investigator deter-
mines that the abnormal value is no longer clinically significant.
For patients who have not previously had genetic testing confirming diagnosis
of achondroplasia, molecular genetic diagnosis to identify the FGFR3 pathogenic
variant (p.(Gly390Arg), p.(Gly346Glu), p.(Gly375Cys), or ‘‘other’’) will be per-
formed locally, within the screening period. If patients had previous genetic testing,
patients must have a report from a certified laboratory with the study specific
mutation documented.
Vital signs will include seated or supine systolic blood pressure and diastolic
blood pressure measured in mmHg, heart rate in beats per minute, respiration rate
in breaths per minute, and temperature in degrees Celsius.
Complete physical examinations will include major body systems, including
assessment of general appearance, cardiovascular function, dermatologic, head,
eyes, ears, nose, and throat, lymphatic, respiratory, gastrointestinal, musculoskele-
tal, and neurological and genitourinary.
A standard 12-lead ECG will be performed and evaluated locally and will
include assessment of heart rate, rhythm, intervals, axis, conduction defects, and
anatomic abnormalities. If clinically significant abnormalities are noted, the
Investigator or designee is required to report it as an Adverse Event and assess
whether it is appropriate for the patient to continue in the study.
Cardiac anatomy and function will be evaluated by a standard two-dimensional
Doppler echocardiogram by a local cardiologist. Echocardiograms will provide
information regarding cardiac anatomy and function prior to enrollment and at
the end of the study.
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Data monitoring committee
In addition to safety monitoring by BioMarin personnel, an independent Data
Monitoring Committee will act as an advisory body and will monitor the safety of
patients in the study. If a study patient requires cervicomedullary decompression
surgery, the committee will be informed and provided all available information for
review. The Data Monitoring Committee will make recommendations for stopping
or continuing the study on an individual patient level or on a study level according
to the pre-specified criteria. The Data Monitoring Committee may also make
endorsements for dose adjustments if needed.
Efficacy outcome assessments
Signs and symptoms of foramen magnum stenosis leading to cervicomedullary
compression will be assessed and monitored during this study using a combination
of data from MRI, neurological examinations, polysomnography, and condition
specific developmental milestone acquisition.
Magnetic resonance imaging assessments
MRI assessments will be performed to evaluate the effect of vosoritide on the the
skull and the brain (including volumes of the face, sinuses, calvarium, brain, and
ventricles; and dimensions of the foramen magnum and relations to surrounding
structures) as well as the whole spinal cord (including relations to the spinal canal).
MRI will be carried out at screening, then biannually at weeks 26, 52, 78, and 104
and annually thereafter.
The MRI assessment procedures will be performed under general anesthesia,
with the head in a neutral position and according to pre-defined parameters as
shown in Table 3 (Brainstem and Skull) and Table 4 (Thoracolumbar Spine).
Independent, blinded expert review of all MRI assessments will be performed to
standardize eligibility assessment and interpretation of any changes observed dur-
ing the study. Any decisions on whether surgery is required will remain the respon-
sibility of the investigators and neurosurgeons at each participating site, who will
be blinded to the AFMS assigned to their patients by the independent reviewer.
Neurological examination
To evaluate the effect of vosoritide on neurological signs and symptoms of cervico-
medullary compression, complete neurological examinations will be performed at
all visits, including assessment of lower cranial nerves, sensory and motor examina-
tions, spinal reflexes, co-ordination, and gait.
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Age-specific developmental milestone acquisition
To assess the effect of vosoritide on age-specific developmental milestones, Bayley-
III scores will be used according to age throughout the course of the study. The
Bayley-III is a performance-based outcome assessment for use in children from 1
to 42months. It is individually administered by the trained clinician to the patient/
child. Scales include Cognitive subscale, Receptive and Expressive subscales, and
Gross and Fine Motor subscales. The two language scales make up a composite
Language Scale score and the Gross and Fine Motor subscales yield a composite
Motor Scale score. The scales have clinical and research utility as a diagnostic
assessment for young children with varied disorders and disabilities and reflect cur-
rent professional standards for early childhood assessment.36
Sleep study
Polysomnography will be used to assess the presence and severity of sleep-
disordered breathing by measurement of blood oxygen saturation, pulse rate, and
airflow during overnight monitoring. Assessment of episodes of sleep apnea will
include the number of episodes of apnea and hypopnea per hour (Apnea/
Hypopnea Index).
Table 3. MRI parameters for the brainstem and skull.
Parameter Description
Superior extent Vertex of skull (one slice above skull)
Inferior extent Cervical C4 (ensure the bottom of the chin is included in
the image volume)
Sequences Scout
Sagittal 3D T1-weighted image (T1WI)
Sagittal 3D T2-weighted image (T2WI)
Axial and coronal reconstructions of the Sagittal T1 and T2
Plane Sagittal (T2 and T1)
Reconstruction (MPR) plane Axial and coronal
Slice thickness 1.2mm or less for 3D Sagittal
1mm for reconstruction scans
Interslice gap (Spacing) 0mm
Matrix 2563 256 highly recommended
FOV 20–25 cm required
NEX 1–2
Number of slices Sagittal T1 and T2 should have the same number of slices.
Follow up timepoint must be consistent with screening.
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Anthropometric measurements
Anthropometric measurements will be taken during study visits with each measure-
ment taken in triplicate and conducted using standardized techniques using the
same equipment across all study sites.
Statistical analysis
Approximately 20 patients aged 0months to 12months at study entry will partic-
ipate in this study. No formal sample size calculations were performed but the
number of patients is considered appropriate to evaluate the safety and efficacy of
vosoritide in this at-risk population.
The statistical analysis plan will provide additional details on the planned statis-
tical analysis. Unless otherwise stated, all analyses will be performed using SAS v.
9.4. Because the completeness of the data affects the integrity and accuracy of the
interim and final study analysis, every effort will be made to ensure complete, accu-
rate, and timely data collection and, therefore, avoid missing data. Missing data
will not be imputed in any of the summaries, with the exception of missing dates
for medications or adverse events. Any patient who prematurely discontinues study
drug will be encouraged to continue to participate in the study assessments for the
remaining duration of the study, as long as in the judgment of the Investigator such
continued participation would not detrimentally affect the health, safety, or welfare
of the patient.
Efficacy and safety data will be summarized descriptively by study treatment
allocation; no confirmatory statistical testing will be performed and differences
Table 4. MRI parameters for the thoracolumbar spine.
Parameter Description
Superior extent Vertex of T11 (one slice above T11). Bony detail should be
visible from T-11
Inferior extent Infracoccygeal (one slice below the tip of the coccyx)
Sequences Scout
Sagittal T1-weighted image (T1WI)
Sagittal T2-weighted image (T2WI)
Axial T1-weighted image (T1WI)
Axial T2-weighted image (T2WI)
Axial T2 gradient echo
Plane Sagittal and axial
Slice thickness 3mm
Interslice gap (spacing) 0mm
Matrix 2563 256 highly recommended
FOV 20–25 cm required
NEX 1–2
Number of slices Follow up timepoint must be consistent with screening.
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between treatment arms will be provided with 95% confidence intervals.
Summaries of the continuous data will include the number of patients with assess-
ments, mean, SD, median, 25th and 25th percentile, minimum and maximum, and
95% confidence limits. The frequency and incidence will be presented for categori-
cal data.
Safety analyses
The safety analysis will be performed on the Safety Population. The MedDRA dic-
tionary will be used to assign system organ class and preferred term classification
to events and diseases, based on the original terms entered on the electronic case
report form (eCRF).
The incidence of AEs will be summarized by system organ class, preferred term
and study treatment allocation. All AEs, including SAEs and AEs that lead to per-
manent discontinuation from the study and from the study treatment, will be listed.
Events of Interest such as hypersensitivity reactions, injection site reactions and
symptomatic hypotension, and the percentage of patients who report these AEs
will be presented.
Clinical laboratory data will be summarized by the type of laboratory test. For
each clinical laboratory test, descriptive statistics will be provided on baseline as
well as all subsequent visits. Shift tables from baseline to worst post-baseline value
based on the Common Terminology Criteria Grading (Normal—Grade 5) will be
generated.
All other safety measures including vital signs, physical examination, ECG,
echocardiograms, and concomitant medication data will also be summarized
descriptively. All safety results will be listed.
Efficacy analysis
The efficacy analysis will be performed on the Final Analysis Set (FAS) consisting
of all randomized consented patients. Analyses to evaluate efficacy endpoints
include:
 Frequency of surgical cervicomedullary decompression over the course of
the study.
 Change in clinical signs and symptoms (including neurological assessment)
every 6months.
 Change in MRI measurement of area of foramen magnum and antero-
posterior (AP) diameter, brain stem, and spinal cord volume and ratio of
area of spinal cord to foramen magnum every 6months.
 Change in MRI measurement of area of spinal canal, transverse and AP dia-
meter, spinal cord volume and ratio of area of spinal cord to spinal canal
every 6months.
 Change in developmental skills (Bayley-III) every 6months.
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 Change in status of sleep apnea including central and obstructive compo-
nents (sleep study) every 6months.
 Change in anthropometric measurements every 6months.
Descriptive summaries at each visit, including change from baseline (defined as
date of randomization), will be provided by study treatment allocation and strata
in which patients are enrolled.
Conclusion
Abnormal development and growth of the foramen magnum in infants and young
children with achondroplasia, leading to compression of the brainstem and other
vital structures passing through the cranio-cervical junction, is the most important
factor leading to increased mortality and morbidity in these children in the first
5 years of life. Similarly, impaired growth of the spinal canal results in spinal canal
stenosis and cord compression leading to significant morbidity later in adulthood.
It follows that one of the key goals of any precision therapy aimed at improving
the impaired endochondral ossification that lies at the source of this condition, is
to improve and restore the growth rate of the foramen magnum and spinal canal.
The recent advent of vosoritide, combined with its safety profile, and promising
effects on long bone growth in children with achondroplasia aged 5 to 18 years,
allows us to hypothesize whether treatment of infants and young children with this
therapy might be safe and have a positive effect on growth of the foramen magnum
and spinal canal, decreasing consequent medical complications.
It is hoped that the underlying rationale, design and methods of this pioneering
clinical trial will begin the journey to answering this key question, with potential
life-saving or health-improving benefits for young children born with achondropla-
sia. It will also serve as a benchmark against which other potential therapies for
achondroplasia (currently in early clinical development) can be assessed.37
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